

NEW ZEALAND MEDICINAL  
CANNABIS SUMMIT

Aotea Centre, Auckland

Pre-Summit Workshops – 9 November 2020 |

Summit – 10 November 2020

Pre-Summit Workshops and  
Main Summit Programme  
Overview

**M E D**  
**2 0 2 0 C A N**

## Pre Summit Workshops – Monday 9 November 2020

These workshops are a mix of presentations from our international and national speakers, followed by round table discussions with the speakers to answer all the questions you have for experts in their field.

### Industry deep dive workshops

#### Room 1: Regulatory landscape for medicinal cannabis in New Zealand


Understand the current position from New Zealand Government agencies regarding medicinal cannabis as an economic growth opportunity



9:00am	<b>Karakia and official opening</b>
9:10am	<b>Welcome</b> Tanya Wilson, Māori Business and Relationship Manager, Callaghan Innovation
9:15am	<b>Government roadmap overview and update</b> Andrew Cameron Principal Consultant, HealthiNZ
9:30am	<b>Medicinal Cannabis Agency and the New Zealand environment</b> To be confirmed
10:00am	Morning Tea
10:30am	<b>Panel Discussion: Lessons learned from other countries</b>  Facilitator & Asia/Pacific USA/Canada Recent emerging environments  Martin Woodbridge, International Consultant, Woodbridge Research Brent Zettl, President and CEO, ZYUS Life Sciences Inc. Rhys Cohen, Principal Consultant, FreshLeaf Analytics
12:00pm	Lunch break

	<b>Room 1: Research in medicinal cannabis: application of current evidence and future considerations</b> The role of clinical trials and evidence-based medicine in the medicinal cannabis sector and New Zealand's role 	<b>Room 2: Seed to sale</b> Meet and discuss with industry along the supply chain seed to sale
	<b>Facilitator for the day</b> <b>Simon Carson</b> Medical Director, <b>Southern Clinical Trials Group Ltd</b>	<b>Facilitator for the day</b> <b>Tanya Wilson</b> , Māori Business and Relationship Manager, <b>Callaghan Innovation</b>
1:00pm	<b>The endocannabinoid system and therapeutic indications for CBD &amp; THC</b> <b>Dr David Hepburn, MD</b> , Medical Director, <b>Plena Global</b>	<b>New Zealand's Competitive advantage</b> <b>Martin Woodbridge</b> , International Consultant, <b>Woodbridge Research</b>
1:30pm	<b>Opportunity for New Zealand Clinical Trials Sector</b> <b>Dr Mike Williams</b> Director, <b>Lakeland Clinical Trials Group</b>	<b>Round table discussion (tables)</b> <ol style="list-style-type: none"> <li>1. Growing, processing and manufacturing</li> <li>2. Quality, formulation, and testing</li> <li>3. Regulations</li> </ol>

	<p><b>Room 1: Research in medicinal cannabis: application of current evidence and future considerations</b> The role of clinical trials and evidence-based medicine in the medicinal cannabis sector and New Zealand's role</p> 	<p><b>Room 2: Seed to sale</b> Meet and discuss with industry along the supply chain seed to sale</p>
2:00pm	<p><b>Q&amp;A with international and national cannabis experts</b></p> <p>Panel facilitator -<b>Sharlene Mavor</b>, Medical Scientist, <b>Medical Cannabis Research Australia</b></p> <p><b>Paul Mavor</b>, Pharmacist, <b>Health House International Pty Ltd</b></p> <p><b>Dr. Adele Hosseini</b>, Chief Scientific Officer, <b>Bod Australia</b></p> <p><b>Dr Mike Williams</b>, Director, <b>Lakeland Clinical Trials Group</b></p>	<p><b>1. Growing, processing and manufacturing</b></p> <p>Facilitator: <b>Richard Campbell</b> – Investment Manager <b>New Zealand Trade and Enterprise</b></p> <p>Experts: <b>Tom Forrest</b> CF, Founder &amp; Horticultural Specialist, <b>Indicated Technology</b> <b>Dr James Polston</b>, Chief Science Officer, <b>Helius Therapeutics</b></p> <p><b>2. Quality, formulation, and testing</b></p> <p>Facilitator: <b>Rahau Shirazi</b>, Customer Manager <b>Callaghan Innovation</b></p> <p>Experts: <b>Andy Herbert</b>, Pharmaceutical Manufacturing Consultant, <b>Bioboy Limited</b>, <b>Dr Mary-Jane McCarthy</b>, ESR's Forensic Specialised Analytical Services Manager, <b>ESR</b></p> <p><b>3. Regulations</b></p> <p>Facilitator: <b>Simon Yarrow</b>, <b>Callaghan Innovation</b></p> <p>Experts: <b>To be Confirmed</b></p> <p><b>Tara Creaven-Capasso</b>, Director / Founding Partner, <b>Caduceus Medical Development, Ltd</b></p> <p>IP lawyer across all tables:</p> <p><b>Helen Bellchambers</b>, Senior Associate, <b>AJPark</b></p> <p><b>Dr James Robinson</b>, PhD, Principal, <b>AJPark</b></p>

	<b>Room 1: Research in medicinal cannabis: application of current evidence and future considerations</b> The role of clinical trials and evidence-based medicine in the medicinal cannabis sector and New Zealand's role 	<b>Room 2: Seed to sale</b> Meet and discuss with industry along the supply chain seed to sale
3:00 pm	Afternoon Tea	
3:30pm	<b>"What we've learned in 500 days of Prescribing Medicinal Cannabis in Australia"</b> <b>Dr Benjamin Jansen</b> Chairman & Clinical Director, <b>Cannabis Doctors Australia</b>	<b>Round table discussion (tables)</b> 1. Growing, processing and manufacturing 2. Quality, formulation, and testing 3. Regulations
3:50pm	<b>Australian and New Zealand trends on medicinal cannabis use</b> <b>Dr Geoff Noller, PhD</b> Research Consultant, Substance Use and Policy Analysis, <b>University of Otago</b> <b>Rhys Cohen</b> , Principal Consultant, <b>FreshLeaf Analytics</b>	<b>Round table discussion (tables)</b> 1. Growing, processing and manufacturing 2. Quality, formulation, and testing 3. Regulations
4:30pm	<b>Q&amp;A</b>	<b>Q&amp;A</b>

# Main Summit – Tuesday 10 November 2020

## Morning Programme

**M E D**  
2020 **C A N**

The educational component of "MedCan Summit 2020", has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 12.5 CME credits for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.

This endorsement is for the educational components of the MedCan Summit only. It is not an endorsement of the MedCan Summit itself, nor of NZTech or BioTechNZ.




### MORNING KEYNOTE SESSIONS

8:30am	<b>Karakia and official opening</b>
8:40am	<b>Welcome</b> <b>Zahra Champion</b> , Executive Director, <b>BioTechNZ</b>
8:50am	<b>The history of cannabis as a medicine – Video keynote address</b> <b>Professor Raphael Mechoulam</b> , Professor, <b>Hebrew University of Jerusalem</b>
9:00am	<b>Opening Address</b> To be confirmed
9:50am	<b>Medical cannabis: Presenting the facts, dispelling the myths</b> <b>Dr David Hepburn</b> , MD, Medical Director, <b>Plena Global</b>
10:30am	Morning Tea


Key: CME Programme

	MEDICINE 	SCIENCE	INDUSTRY
	MC: Dr Richard Acland	MC: Dr Anna Campbell, PhD	MC: Graeme Muller
11:00am	<p><b>Current issues with the stigma of cannabis</b> Dr David Hepburn, MD, Medical Director, Plena Global</p>	<p><b>Panel discussion: Crown Research Industries (CRI's) supporting the medicinal cannabis</b> Moderator: Dr Trevor Stuthridge, PhD, Research Director, AgResearch Dr Stefan Hill, PhD, Scientist, Scion Dr Richard Newcomb, PhD, Chief Scientist, Plant &amp; Food Research Dr Mary-Jane McCarthy, PhD, Forensic Toxicology Manager, Institute of Environmental Science and Research</p>	<p><b>Introduction and cannabis and the New Zealand landscape and the impact of international regulations</b> Martin Woodbridge, International Consultant, Woodbridge Research</p>
11:25am	<p><b>The evidence and experience for neuropathic pain</b> Dr Giresh Kanji, Musculoskeletal Pain Specialist, Consultant</p>	<p><b>The chemistry and pharmacology of cannabis</b> Dr Kevin Spelman, PhD, Molecular Biologist, Phytochemist and Clinician, National University of Natural Medicine</p>	<p><b>The Business 101 Guide for the Cannabis Frontier:</b> Brent Zettl, President and CEO, ZYUS Life Sciences Inc.</p>
11:50am	<p><b>Current evidence and practical experience for cannabinoid- based medicines in chronic pain and palliative care management</b> Dr Maria-Fernanda Arboleda MD, International Director Medical Services, Khiron Life Sciences Corp</p>	<p><b>Natural product scaffolds for the development of new drugs</b> Dr Samuel Banister, PhD, Team Leader in Medicinal Chemistry, The University of Sydney</p>	<p><b>An unexpected journey, from biotech to cannabis medicine and back again</b> Dr Stewart Washer, PhD, Executive Chairman, Emerald Clinics</p>

	MEDICINE 	SCIENCE	INDUSTRY
	MC: Dr Richard Acland	MC: Dr Anna Campbell, PhD	MC: Graeme Muller
12:15pm	<b>Clinical Data</b> Speaker to be confirmed	<b>Protecting your intellectual property, opportunities and risks</b> Helen Bellchambers, Senior Associate, <b>AJPark</b>	<b>Medicinal cannabis from a grower's perspective</b> Tom Forrest, Founder & Horticultural Specialist, <b>Indicated Technology</b>
12:40pm Lunch (allowing for social distancing)			
1:40pm			
2:05pm	<b>Medicinal cannabis use in New Zealand</b> Dr Graham Gulbransen, FRNZCGP, FACHAM Cannabis Consultant, GP and Addiction Specialist	<b>Regulatory and scientific rigor in medicinal cannabis</b> Dr. Adele Hosseini, Chief Scientific Officer, <b>Bod Australia</b>	<b>Extraction of cannabis: Options, current industrial practice, and future trends</b> Dr Stephen Tallon, PhD, Team Leader, Process Engineering Group, <b>Callaghan Innovation</b>
2:30pm	<b>Dispelling the myths of THC</b> Dr Mark A. Ware MBBS MRCP (UK) MSc Chief Medical Officer, <b>Canopy Growth Corporation</b>	<b>Opportunities and case studies of medicinal cannabis clinical trials</b> To be confirmed	<b>Disruptive technologies and new opportunities in the cannabis sector (Action)</b> Panel to be confirmed



Main Summit – Tuesday 10 November 2020  
Afternoon Programme

	MEDICINE 	SCIENCE	INDUSTRY
2:55pm	<b>Pharmaceutical cannabis for healthcare professionals</b>  <b>Paul Mavor</b> , Pharmacist, <b>Health House International Pty Ltd</b>	<b>The data collection systems NZ and Australia</b>  <b>Dr Geoff Noller, PhD</b> Research Consultant, Substance Use and Policy Analysis, <b>University of Otago</b>  <b>Rhys Cohen</b> , Principal Consultant, <b>FreshLeaf Analytics</b>	<b>Key requirements for GMP manufacturing</b>  <b>Richard Keene</b> , Consultant, <b>Keene Manufacturing Solutions</b>
3:10pm Afternoon Tea			
AFTERNOON KEYNOTE SESSIONS			
	MC Dr Andrew Kelly PhD		
3:50pm	<b>The NZ regulatory environment, and implications for prescribers and patients and industry</b> <b>Chris James</b> , Group Manager, Medsafe, <b>Ministry of Health</b>		
4:10pm	<b>Case Study of a Large-Scale United States Medical Cannabis Research Investigation: Insight into Florida Medical Cannabis Usage and Outcomes.</b> <b>Dr James Polston PhD</b> , Chief Science Officer, <b>Helius Therapeutics</b>		
4:30pm	<b>Panel discussion: Patients perspective</b>		
4:50pm	<b>Closing Remarks</b>		
5:00pm Close			



NEW ZEALAND MEDICINAL  
CANNABIS SUMMIT

[www.medcansummit.co.nz](http://www.medcansummit.co.nz)

PRINCIPAL SPONSOR



**M E D**  
**2020 C A N**